[go: up one dir, main page]

PE20181378A1 - Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b - Google Patents

Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b

Info

Publication number
PE20181378A1
PE20181378A1 PE2018001330A PE2018001330A PE20181378A1 PE 20181378 A1 PE20181378 A1 PE 20181378A1 PE 2018001330 A PE2018001330 A PE 2018001330A PE 2018001330 A PE2018001330 A PE 2018001330A PE 20181378 A1 PE20181378 A1 PE 20181378A1
Authority
PE
Peru
Prior art keywords
dihydroquinoline
cyp11b
ona
inhibitors
derivative
Prior art date
Application number
PE2018001330A
Other languages
English (en)
Inventor
Johannes Aebi
Kurt Amrein
Serena Maria Fantasia
Benoit Hornsperger
Bernd Kuhn
Yongfu Liu
Hans P Maerki
Alexander V Mayweg
Peter Mohr
Michelangelo Scalone
Xuefei Tan
Mingwei Zhou
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963698&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20181378(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20181378A1 publication Critical patent/PE20181378A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se refiere compuestos biciclicos derivados de dihidroquinolina-2-ona de formula I en los que R1, R2, R3, R4, R5, R8, R9, R10 son H, alquilo, haloalquilo, cicloalquilo, halocicloalquilo; R6, R7, R12, son H, halogeno, alquilo, haloalquilo, cicloalquilo, entre otros; A1 es N o CR13; A2 es NR14, entre otros; A3 es N o CR17; n es cero, 1 o 2. Dichos compuestos son utiles para terapia o profilaxis de enfermedad renal cronica, fallo cardiaco congestivo, hipertension, aldosteronismo primario, entre otros. Entre los compuestos preferidos tenemos los siguientes: (rac)-N-[4-(1-metil-2-oxo-1,2,3,4-tetrahidro-quinolin-6-il)-5,6,7,8-tetrahidro-isoquinolin-8-il)propionamida; (rac)-N-[4-(1-metil-2-oxo-1,2,3,4-tetrahidroquinolin-6-il)-5,6,7,8-tetrahidroisoquinolin-8-il)etanosulfonamida; entre otros.
PE2018001330A 2011-09-23 2012-09-20 Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b PE20181378A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2011080078 2011-09-23

Publications (1)

Publication Number Publication Date
PE20181378A1 true PE20181378A1 (es) 2018-09-05

Family

ID=46963698

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2018001330A PE20181378A1 (es) 2011-09-23 2012-09-20 Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b
PE2014000393A PE20141042A1 (es) 2011-09-23 2012-09-20 Nuevos derivados biciclicos de dihidroquinolina-2-ona

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2014000393A PE20141042A1 (es) 2011-09-23 2012-09-20 Nuevos derivados biciclicos de dihidroquinolina-2-ona

Country Status (34)

Country Link
US (1) US9353081B2 (es)
EP (1) EP2758388B1 (es)
JP (1) JP6012737B2 (es)
KR (1) KR101723276B1 (es)
CN (1) CN103827101B (es)
AR (1) AR087984A1 (es)
AU (1) AU2012311582B2 (es)
BR (1) BR112014006660B1 (es)
CA (1) CA2845170C (es)
CL (1) CL2014000663A1 (es)
CO (1) CO6870035A2 (es)
CR (1) CR20140089A (es)
DK (1) DK2758388T3 (es)
EA (1) EA035108B1 (es)
EC (1) ECSP14013264A (es)
ES (1) ES2666802T3 (es)
HR (1) HRP20180592T1 (es)
HU (1) HUE038773T2 (es)
IL (1) IL230874A (es)
LT (1) LT2758388T (es)
MX (1) MX366095B (es)
MY (1) MY186165A (es)
NO (1) NO2758388T3 (es)
PE (2) PE20181378A1 (es)
PH (1) PH12014500584A1 (es)
PL (1) PL2758388T3 (es)
PT (1) PT2758388T (es)
RS (1) RS57139B1 (es)
SG (1) SG2014010599A (es)
SI (1) SI2758388T1 (es)
TW (1) TWI576342B (es)
UA (1) UA115972C2 (es)
WO (1) WO2013041591A1 (es)
ZA (1) ZA201401577B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
EP2838883B1 (en) * 2012-04-17 2017-11-08 F. Hoffmann-La Roche AG New phenyl-tetrahydroisoquinoline derivatives
US9783543B2 (en) 2012-11-19 2017-10-10 Bayer Pharma Aktiengesellschaft Aminoimidazopyridazines
BR112015023280A2 (pt) * 2013-03-14 2017-07-18 Hoffmann La Roche derivados de dihidroquinolin-2-ona para utilização como inibidores da aldosterona sintase
DK3004077T3 (da) * 2013-05-27 2020-01-13 Hoffmann La Roche Nye 3,4-dihydro-2H-isoquinolin-1-on- og 2,3-dihydro-isoindol-1-on-forbindelser
KR102217285B1 (ko) * 2013-05-27 2021-02-22 에프. 호프만-라 로슈 아게 신규한 3,4-다이하이드로-2h-이소퀴놀린-1-온 및 2,3-다이하이드로-이소인돌-1-온 화합물
RS59663B1 (sr) * 2013-05-27 2020-01-31 Hoffmann La Roche Nova jedinjenja 3,4-dihidro-2h-izokinolin-1-on i 2,3-dihidro-izoindol-1-on
CN105593212B (zh) * 2013-10-17 2019-06-04 豪夫迈·罗氏有限公司 作为醛固酮合酶抑制剂的苯基-二氢吡啶衍生物
RU2016116435A (ru) * 2013-10-17 2017-11-22 Ф. Хоффманн-Ля Рош Аг Производные фенил-дигидропиридина в качестве ингибиторов альдостеронсинтазы
CA2915788A1 (en) * 2013-10-17 2015-04-23 F. Hoffmann-La Roche Ag New phenyl-dihydropyridine derivatives as aldosterone synthase inhibitors
EP3212638B1 (en) * 2014-10-31 2019-11-20 F.Hoffmann-La Roche Ag New dihydroquinoline pyrazolyl compounds as aldosterone synthase inhibitors
WO2016066597A1 (en) * 2014-10-31 2016-05-06 F. Hoffmann-La Roche Ag New dihydroquinoline pyrazolyl compounds
JP6669734B2 (ja) * 2014-10-31 2020-03-18 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピラゾリル−3,4−ジドヒドロキノリン−2−オン・アルドステロン合成酵素阻害剤
US9890171B2 (en) 2014-12-02 2018-02-13 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
SG11201810847RA (en) 2016-06-10 2019-01-30 Nihon Mediphysics Co Ltd Non-invasive diagnostic imaging agent for heart disease
WO2020223267A1 (en) 2019-05-01 2020-11-05 Boehringer Ingelheim International Gmbh (r)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate
US20240277698A1 (en) * 2021-06-24 2024-08-22 Cincor Pharma, Inc. Methods of using aldosterone synthase inhibitors
WO2023063851A1 (en) * 2021-10-13 2023-04-20 «Target Medicals» Limited Liability Company Inhibitors of human aldosterone synthase (cyp11b2)
CN118401241A (zh) 2021-12-14 2024-07-26 勃林格殷格翰国际有限公司 用于治疗慢性肾脏病的醛固酮合成酶抑制剂
KR20250057804A (ko) 2022-09-02 2025-04-29 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
EP4574830A1 (en) * 2022-09-23 2025-06-25 Guangzhou Vinnocent Pharmaceutical Limited Annelated pyridine steroid synthetase inhibitor, preparation method therefor, and use thereof
EP4624464A1 (en) * 2022-11-23 2025-10-01 Shanghai Hansoh Biomedical Co., Ltd. Pyridine polycyclic compound inhibitor, preparation method therefor and use thereof
TW202446391A (zh) * 2023-04-28 2024-12-01 大陸商長春金賽藥業有限責任公司 Cyp11b2抑制劑化合物、藥物組合物及其用途
WO2024235165A1 (zh) * 2023-05-12 2024-11-21 南京明德新药研发有限公司 含氮杂环类化合物及其应用
WO2025002335A1 (zh) * 2023-06-29 2025-01-02 苏州科睿思制药有限公司 Baxdrostat的晶型及其制备方法和用途
TW202504603A (zh) * 2023-07-21 2025-02-01 大陸商上海翰森生物醫藥科技有限公司 三并環類化合物、及其製備方法和應用
US12427185B2 (en) 2023-09-05 2025-09-30 E-Star Biotech, LLC Formulations of MANP and uses thereof
CN117247371A (zh) * 2023-09-18 2023-12-19 上海相辉医药科技有限公司 一种cyp11b2抑制剂baxdrostat的制备方法
TW202519227A (zh) * 2023-11-10 2025-05-16 大陸商上海齊魯製藥研究中心有限公司 稠環衍生物、其製備方法及其在醫藥上的應用
TW202525278A (zh) 2023-12-15 2025-07-01 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 治療慢性腎病及高血壓之方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4792561A (en) * 1986-05-29 1988-12-20 Syntex (U.S.A.) Inc. Carbostyril derivatives as combined thromboxane synthetase and cyclic-AMP phosphodiesterase inhibitors
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
US5246944A (en) * 1991-08-13 1993-09-21 Merck & Co., Inc. Quinoline angiotensin ii antagonists incorporating a substituted benzyl element
WO2005065050A2 (ja) * 2003-12-25 2005-07-21 Asahi Kasei Pharma Corporation 2環化合物
JP5202327B2 (ja) 2005-12-09 2013-06-05 アムジエン・インコーポレーテツド プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2

Also Published As

Publication number Publication date
AU2012311582A1 (en) 2014-02-20
CA2845170A1 (en) 2013-03-28
AR087984A1 (es) 2014-04-30
US20130079365A1 (en) 2013-03-28
CO6870035A2 (es) 2014-02-20
CN103827101A (zh) 2014-05-28
KR20140076591A (ko) 2014-06-20
JP2014526539A (ja) 2014-10-06
SG2014010599A (en) 2014-04-28
EP2758388B1 (en) 2018-02-21
LT2758388T (lt) 2018-05-10
WO2013041591A1 (en) 2013-03-28
DK2758388T3 (en) 2018-05-07
EA201490567A1 (ru) 2014-07-30
CL2014000663A1 (es) 2014-10-03
IL230874A0 (en) 2014-03-31
NO2758388T3 (es) 2018-07-21
NZ620652A (en) 2016-09-30
MY186165A (en) 2021-06-30
ZA201401577B (en) 2015-01-28
PE20141042A1 (es) 2014-08-27
KR101723276B1 (ko) 2017-04-04
ES2666802T3 (es) 2018-05-07
HUE038773T2 (hu) 2018-11-28
US9353081B2 (en) 2016-05-31
CA2845170C (en) 2019-08-13
HRP20180592T1 (hr) 2018-05-18
IL230874A (en) 2016-07-31
CR20140089A (es) 2014-03-21
MX2014002624A (es) 2014-04-14
MX366095B (es) 2019-06-27
PT2758388T (pt) 2018-04-17
CN103827101B (zh) 2016-12-07
RS57139B1 (sr) 2018-07-31
PL2758388T3 (pl) 2018-08-31
BR112014006660B1 (pt) 2021-08-17
TWI576342B (zh) 2017-04-01
JP6012737B2 (ja) 2016-10-25
ECSP14013264A (es) 2014-04-30
AU2012311582B2 (en) 2017-07-06
BR112014006660A2 (pt) 2017-04-04
EP2758388A1 (en) 2014-07-30
TW201319054A (zh) 2013-05-16
PH12014500584A1 (en) 2017-04-26
SI2758388T1 (en) 2018-05-31
EA035108B1 (ru) 2020-04-28
UA115972C2 (uk) 2018-01-25

Similar Documents

Publication Publication Date Title
PE20181378A1 (es) Compuestos biciclicos derivados de dihidroquinolina-2-ona como inhibidores de cyp11b
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
EA201791873A1 (ru) Полиморф ингибиторов syk
PE20160546A1 (es) Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4
PE20161064A1 (es) Derivado de sulfonamida o sales de adicion de acido farmaceuticamente aceptables del mismo
CR20120275A (es) Derivados benzamida sustituidos
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств
MA35089B1 (fr) Inhibiteurs de la production de leucotrienes de type benzodioxane
AR087148A1 (es) Imidazopiridazinas
PE20130155A1 (es) Derivados de ariletinilo
PE20151602A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3
MX2012005358A (es) Procedimiento para la preparacion de etexilato de dabigatran.
AR052866A1 (es) Fenil-metanonas monociclicas sustituidas
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
BR112014013136A2 (pt) novos derivados de dihidroisoquinolina-1-ona biciclicos
EA201490272A1 (ru) Новые 4-пиперидинильные соединения для применения в качестве ингибиторов танкиразы
MA39152A1 (fr) Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine
PE20170946A1 (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
PE20142282A1 (es) Nuevos derivados de aril-quinolina
AR092555A1 (es) 2-oxo-2,3-dihidro-indoles y su utilizacion para el tratamiento de trastornos del snc
PE20141553A1 (es) Compuestos de triazolopiridina como inhibidores de la ped10a
EA201170074A1 (ru) Изохинолиноновые производные в качестве антагонистов nk3
ES2571577T3 (es) Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2
PE20140629A1 (es) Derivados de fenil-isoxazol y procedimiento para la preparacion de los mismos
CO6300944A2 (es) Derivado de hidroxi-quinoxalin-carboxamida